Ignite Creation Date:
2024-05-06 @ 2:18 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04270760
Status:
COMPLETED
Last Update Posted:
2023-09-07
First Post:
2020-02-13
Brief Title:
Olpasiran Trials of Cardiovascular Events And LipoproteiNa Reduction - DOSE Finding Study
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Double-blind Randomized Placebo-controlled Phase 2 Study to Evaluate Efficacy Safety and Tolerability of Olpasiran AMG 890 in Subjects With Elevated Lipoproteina
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the effect of olpasiran administered subcutaneously SC compared with placebo on percent change from baseline in lipoproteina Lpa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-003688-23 | EUDRACT_NUMBER | None | None |